Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Outlook Therapeutics's revenue for the twelve months ending Sep 30, 2019 was $8.15M, up 163.8% year over year. For fiscal 2025 it was $1.41M, down 82.6% from the year before. The highest annual figure on record is $8.15M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.41M | -82.6% |
| FY2019 | Sep 30, 2019 | $8.15M | +163.8% |
| FY2018 | Sep 30, 2018 | $3.09M | -19.0% |
| FY2017 | Sep 30, 2017 | $3.81M | +27.9% |
| FY2016 | Sep 30, 2016 | $2.98M | -42.9% |
| FY2015 | Sep 30, 2015 | $5.22M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $1.51M | +41.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $5.85M | +658.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $583.85K | -24.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $641.14K | -16.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $1.07M | +38.3% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $771.89K | -73.4% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $771.89K | +154.6% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $771.89K | +154.6% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $771.89K | +154.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.90M | +486.4% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $303.14K | -38.7% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $303.14K | -69.5% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $303.14K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $494.89K | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $494.89K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $994.89K | – |
See a number that looks wrong?